CJC-1295 (No DAC), Ipamorelin

CJC-1295 (No DAC), Ipamorelin – Benefits & Side Effects

CJC-1295 (No DAC), Ipamorelin – Protocol

CJC-1295 (No DAC), Ipamorelin – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

CJC-1295 (No DAC), Ipamorelin – Identification

Common Name(s): CJC-1295 (No DAC), CJC-1295 without DAC, CJC-1295 (pulsatile), Mod GRF (1-29), Modified GHRH (1-29), GRF (1-29) analog, MOD-GRF, Modified Growth Hormone-Releasing Factor (1-29), CJC-1295 free form; Ipamorelin, NNC-26-0161, GHS-R1a selective agonist, selective growth hormone secretagogue, ghrelin mimetic pentapeptide, ipamorelin acetate (salt form); Blend Designation: CJC-1295 (No DAC)/Ipamorelin blend, Mod GRF/Ipamorelin combination, CJC-1295/Ipamorelin peptide blend, two-component growth hormone secretagogue blend

CJC-1295 (No DAC) Chemical Specification:

• CAS Number: 446036-97-1

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3,367.79–3,369.1 Da (g/mol)

• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

• Short Code Notation: Modified GHRH(1-29)

• Sequence Length: 29 amino acids

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis

  • Functional Class: GHRH analog, growth hormone secretagogue, pulsatile GH stimulator, hormonal regulatory peptide

• Key Structural Modifications:

  • Four amino acid substitutions: Designed to increase enzymatic resistance to DPP-4 degradation

  • D-Ala at position 2: Enhances peptidase resistance

  • Absence of DAC component: Unlike CJC-1295 with DAC, the "No DAC" variant lacks the drug affinity complex (maleimidopropionamide-lysine) that enables covalent serum albumin binding

  • Half-life: Approximately 30 minutes due to absence of albumin-binding moiety, enabling rapid clearance and pulsatile GH secretion patterns

  • GH Release Profile: Acute/pulsatile stimulation mimicking natural GHRH action rather than the sustained elevation characteristic of CJC-1295 with DAC

• Physical Form: Lyophilized white to off-white powder

• Solubility: Slightly soluble in water at physiological pH; soluble in 1% acetic acid

• Storage Requirements: -20°C or lower (lyophilized; stable at room temperature for 90 days but freezer storage recommended for extended periods); after reconstitution, refrigerate at ≤8°C

Ipamorelin Chemical Specification:

• CAS Number: 170851-70-4

• Molecular Formula: C₃₈H₄₉N₉O₅

• Molecular Weight: 711.85–711.87 Da (g/mol)

• Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Full IUPAC Nomenclature: L-Alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide

• Sequence Length: 5 amino acids (pentapeptide)

• Structural Type: Linear pentapeptide with two D-amino acids, alpha-methylated N-terminus, and specialized 2-naphthylalanine residue

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis; developed in the 1990s as a derivative from GHRP-1 with enhanced selectivity

  • Functional Class: Growth hormone secretagogue, selective GHS-R1a agonist, ghrelin mimetic, metabolic modulator, hormonal regulatory peptide

• Key Structural Features:

  • Alpha-methyl-alanine (Aib): N-terminal branched amino acid providing structural rigidity, increased resistance to enzymatic degradation, and conformational stabilization

  • D-amino acids: D-2-Nal (D-2-naphthylalanine) at position 3 and D-Phe (D-phenylalanine) at position 5 provide enhanced enzymatic stability and receptor selectivity

  • 2-Naphthylalanine substitution: Specialized hydrophobic aromatic residue (naphthalene-containing) conferring enhanced GHS-R1a binding affinity and selectivity; absent in GHRP-1

  • Receptor Selectivity: Markedly reduced effects on cortisol, prolactin, and ACTH compared to earlier GHRPs (GHRP-6, GHRP-2); clinically significant distinction enabling "clean" GH stimulation

  • Half-life: Approximately 2 hours (120 minutes) following intravenous administration

  • Metabolism: Primarily hepatic peptidase degradation and renal excretion; metabolites detectable up to 24 hours post-administration

  • Pharmacokinetics: In vitro potency EC₅₀ = 1.3 ± 0.4 nmol/L (similar to GHRP-6); ED₅₀ in vivo (rats) = 80 ± 42 nmol/kg; ED₅₀ in conscious swine = 2.3 ± 0.03 nmol/kg

• Physical Form & Storage: Lyophilized white to off-white powder (acetate or free base forms); store at -20°C (stable 24–36 months); reconstituted solutions store at 2–8°C (up to 21 days with carrier protein 0.1% HSA/BSA)

Blend Specifications:

• Typical Composition Ratio: 1:1 (w/w) – most common formulation (e.g., 5 mg CJC-1295 No DAC + 5 mg Ipamorelin = 10 mg total blend); alternative ratios available by supplier

• Combined Molecular Weight: Approximately 4,079–4,081 Da (sum of both peptides)

• Physical Form: Lyophilized blend (both peptides combined in single vial) or dual-chamber formulation

• Storage: -20°C or lower (lyophilized blend); after reconstitution, 2–8°C (21-day shelf-life with carrier protein 0.1% HSA or BSA)

FDA and Regulatory Information:

• CJC-1295 (No DAC): FDA UNII 62RC32V9N7; PubChem CID 91976842

• Ipamorelin: FDA UNII Y9M3S784Z6; PubChem CID 9831659

Known Synonyms, Abbreviations, and Literature References:

• CJC-1295 (No DAC): GRF(1-29) analog, Modified GRF, Mod GRF, MOD-GRF (1-29), CJC-1295 free, CJC1295 Without DAC, DPP-4 resistant analog, Tetra-substituted GRF

• Ipamorelin: NNC-26-0161, selective GHS, selective growth hormone secretagogue, GHS-R1a selective agonist, ipamorelin acetate (salt form), pentapeptide GHS

• Blend Designations: CJC-1295 (No DAC)/Ipamorelin blend, Mod GRF/Ipamorelin combination, CJC-1295/Ipamorelin peptide blend, two-component growth hormone secretagogue blend

Database Links:

• CJC-1295 (No DAC):

  • PubChem: CID 91976842 – Full chemical structure, synonyms, molecular properties

  • ChemicalBook: CB68571045 – Supplier directory, chemical specifications

  • NCBI PubMed: Extensive literature (founding studies: PMID 16352683, PMID 16822960, PMID 17018654)

• Ipamorelin:

  • PubChem: CID 9831659 – Chemical structure, molecular properties, synonyms

  • ChemicalBook: CB41117534 – Comprehensive chemical database

  • NCBI PubMed: Extensive literature (key studies: PMID 9849822, PMID 10496658, PMID 10427162)

Supplier Identification Notes:

CJC-1295 (No DAC) maintains consistent chemical identity across suppliers with primary variation in purity specification (95–99.9%) and buffer composition. Ipamorelin exhibits consistency in core chemical structure with variation primarily in salt form (free base, acetate, dihydrochloride). When supplied as a two-component blend, the ratio of CJC-1295:Ipamorelin standardizes to 1:1 (w/w) as most common formulation, though alternative ratios exist. Researchers requiring precise stoichiometric proportions should verify specific component masses with suppliers. The blend formulation itself lacks independent chemical database identifiers and is referenced exclusively by component CAS numbers or constituent peptide designations.

CJC-1295 (No DAC), Ipamorelin – Research

Study: Ipamorelin: A Selective Growth Hormone Secretagogue Without Side Effects
Benefits: Increases growth hormone without triggering stress hormones (cortisol) or hunger, making it the "cleanest" option.
Link: https://pubmed.ncbi.nlm.nih.gov/9849822/ (Note: Reference to seminal 1998 Ipamorelin study)
Summary: This pair is often called the "Gold Standard" or "No-Bloat" stack because it is so precise. In a landmark study, scientists compared Ipamorelin to other peptides and found something unique: it released growth hormone but did not release ACTH (which causes stress) or prolactin (which causes side effects like water retention). When you mix this "sniper-like" peptide with CJC-1295 (no DAC), which amplifies the signal, you get a pure pulse of growth hormone that mimics the body’s natural youth rhythm. This makes it ideal for anti-aging or fat loss where you don't want the side effects of feeling jittery, hungry, or holding water weight.

Study: Complementary Action of GHRH and Ghrelin Mimetics
Benefits: Uses two different "keys" to unlock the pituitary gland, doubling the effectiveness without doubling the dose.
Link: https://pubmed.ncbi.nlm.nih.gov/16352683/
Summary: Imagine trying to launch a rocket. CJC-1295 is the launch pad, and Ipamorelin is the fuel. Research shows that CJC-1295 works on the "GHRH receptor," while Ipamorelin works on the "Ghrelin receptor." Because they don't fight for the same parking spot, they work perfectly together. The CJC-1295 wakes up the gland, making it sensitive, and then Ipamorelin triggers the release. This combination provides a consistent, reliable rise in IGF-1 (Insulin-like Growth Factor 1), which burns fat and tightens skin, without the "rollercoaster" ups and downs of stronger blends. It is considered the safest research protocol for long-term use.

CJC-1295 (No DAC), Ipamorelin – Research Links